The FDA sent out an update today, February 19, on drugs that are currently in shortage:
- Atropine Sulfate Injection (Updated – Currently in Shortage)
- Calcium Chloride Injection, USP (Updated – Currently in Shortage)
- Cefepime Injection (Updated – Currently in Shortage)
- Epinephrine Injection (Updated – Currently in Shortage)
- Fentanyl Citrate (Sublimaze) Injection (Updated – Currently in Shortage)
- Imipenem and Cilastatin for Injection, USP (Updated – Currently in Shortage)
- Lidocaine Hydrochloride (Xylocaine) Injection (Updated – Currently in Shortage)
- Metoprolol Injection (Updated – Currently in Shortage)
- Piperacillin and Tazobactam (Zosyn) Injection (Updated – Currently in Shortage)
- Potassium Acetate Injection, USP (Updated – Currently in Shortage)
- Potassium Chloride Injection (Updated – Currently in Shortage)
- Sodium Acetate Injection, USP (Updated – Currently in Shortage)
- Sodium Bicarbonate Injection, USP (Updated – Currently in Shortage)
- Sodium Chloride 23.4% Injection (Updated – Currently in Shortage)
- Tobramycin Injection (Updated – Currently in Shortage)
- Vancomycin Hydrochloride for Injection, USP (Updated – Currently in Shortage)
According to the FDA:
“A drug receives Resolved status when the Drug Shortages Staff (DSS) determines that the market is covered, based on information from all manufacturers. The market is considered covered when supply is available from at least one manufacturer to cover total market demand. However, some manufacturers may not have all presentations available. DSS monitors the supply of products with Resolved status. For the most current supply information, contact the manufacturers.”
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
